MannKind (MNKD) 10-Q 12 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2014	5-May-14
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'MNKD	'
Entity Registrant Name	'MANNKIND CORP	'
Entity Central Index Key	'0000899460	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	388,615,163

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$35,759	$70,790
Prepaid expenses and other current assets	3,640	5,485
Total current assets	39,399	76,275
Property and equipment - net	176,337	176,557
State research and development credit exchange receivable - net of current portion	380	298
Other assets	8,437	5,516
Total	224,553	258,646
Current liabilities:	'	'
Accounts payable	3,638	3,860
Accrued expenses and other current liabilities	15,006	21,634
Facility financing obligation	25,871	102,300
Total current liabilities	44,515	127,794
Senior convertible notes	98,662	98,439
Note payable to principal stockholder	49,521	49,521
Other liabilities	14,319	13,605
Total liabilities	207,017	289,359
Commitments and contingencies	'	'
Stockholders' equity (deficit):	'	'
Undesignated preferred stock, $0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at March 31, 2014 and December 31, 2013	'	'
Common stock, $0.01 par value - 550,000,000 shares authorized at March 31, 2014 and December 31, 2013; 386,934,914 and 369,391,972 shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively	3,869	3,697
Additional paid-in capital	2,362,129	2,261,996
Accumulated other comprehensive loss	-4	-4
Deficit accumulated during the development stage	-2,348,458	-2,296,402
Total stockholders' equity (deficit)	17,536	-30,713
Total	$224,553	$258,646

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Undesignated preferred stock, par value	$0.01	$0.01
Undesignated preferred stock, shares authorized	10,000,000	10,000,000
Undesignated preferred stock, shares issued	'	'
Undesignated preferred stock, shares outstanding	'	'
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	550,000,000	550,000,000
Common stock, shares issued	386,934,914	369,391,972
Common stock, shares outstanding	386,934,914	369,391,972

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		277 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Revenue	'	'	$3,166
Operating expenses:	'	'	'
Research and development	26,182	26,398	1,603,474
General and administrative	15,229	10,039	500,615
In-process research and development costs	'	'	19,726
Goodwill impairment	'	'	151,428
Total operating expenses	41,411	36,437	2,275,243
Loss from operations	-41,411	-36,437	-2,272,077
Other income (expense)	-5,890	23	-8,792
Interest expense on note payable to principal stockholder	-714	-1,689	-45,848
Interest expense on notes	-4,042	-2,863	-59,128
Interest income	1	1	37,005
Loss before benefit for income taxes	-52,056	-40,965	-2,348,840
Income tax benefit	'	'	382
Net loss	-52,056	-40,965	-2,348,458
Deemed dividend related to beneficial conversion feature of convertible preferred stock	'	'	-22,260
Accretion on redeemable preferred stock	'	'	-952
Net loss applicable to common stockholders	($52,056)	($40,965)	($2,371,670)
Net loss per share applicable to common stockholders - basic and diluted	($0.14)	($0.15)	'
Shares used to compute basic and diluted net loss per share applicable to common stockholders	368,784	280,058	'

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Loss (USD $)	3 Months Ended		277 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Net loss	($52,056)	($40,965)	($2,348,458)
Other comprehensive loss:	'	'	'
Cumulative translation (loss) gain	'	-2	-4
Unrealized gain (loss) on investments:	'	'	'
Unrealized holding gain (loss) during the period	'	'	48
Less: reclassification adjustment for gains (losses) included in net loss	'	'	-48
Net unrealized (loss) gain on investments	'	'	'
Other comprehensive loss	'	-2	-4
Comprehensive loss	($52,056)	($40,967)	($2,348,462)

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended		277 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'	'
Net loss	($52,056)	($40,965)	($2,348,458)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation and accretion	9,394	3,348	150,228
Stock-based compensation expense	10,937	5,189	194,042
Stock expense for shares issued pursuant to research agreement	'	'	3,018
(Gain) loss on sale, abandonment/disposal or impairment of property and equipment	'	'	25,070
Accrued interest on investments, net of amortization of discounts	'	'	-191
In-process research and development	'	'	19,726
Goodwill impairment	'	'	151,428
Loss on available-for-sale securities	'	'	990
Litigation settlement in stock	'	'	6,494
Fair value of forward purchase contract	'	'	1,237
Other, net	'	-2	1,101
Changes in assets and liabilities:	'	'	'
State research and development credit exchange receivable	-82	-78	-379
Prepaid expenses and other current assets	1,845	690	-1,690
Other assets	'	'	-230
Accounts payable	-1,038	-924	2,309
Accrued expenses and other current liabilities	-6,704	715	32,019
Other liabilities	714	'	1,303
Net cash used in operating activities	-36,990	-32,027	-1,761,983
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'	'
Purchase of marketable securities	'	'	-796,779
Sales and maturities of marketable securities	'	'	796,393
Purchase of property and equipment	-1,409	-1,459	-337,142
Proceeds from sale of property and equipment	'	'	454
Net cash used in investing activities	-1,409	-1,459	-337,074
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Issuance of common stock and warrants, net of issuance costs	1,463	78	1,451,640
Collection of Series C convertible preferred stock subscriptions receivable	'	'	50,000
Issuance of Series B convertible preferred stock for cash	'	'	15,000
Cash received for common stock to be issued	'	'	3,900
Repurchase of common stock	'	'	-1,028
Put shares sold to majority stockholder	'	'	623
Exercise of warrants for common stock	1,938	'	96,085
Borrowings under lines of credit	'	'	4,220
Payment of 2013 notes	'	'	-115,000
Proceeds from notes receivables	'	'	1,742
Proceeds from issuance of facility financing obligation & milestone rights	'	'	119,500
Facility financing obligation & milestone rights issuance costs	'	'	-598
Borrowings on notes payable to principal stockholder	'	'	387,750
Principal payments on notes payable to principal stockholder	'	'	-70,000
Borrowings on notes payable	'	'	3,460
Principal payments on notes payable	'	'	-1,667
Proceeds from senior convertible notes	'	'	207,050
Payment of employment taxes related to vested restricted stock units	-33	-427	-17,861
Net cash provided by (used in) financing activities	3,368	-349	2,134,816
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	-35,031	-33,835	35,759
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	70,790	61,840	'
CASH AND CASH EQUIVALENTS, END OF PERIOD	35,759	28,005	35,759
SUPPLEMENTAL CASH FLOWS DISCLOSURES:	'	'	'
Cash paid for income taxes	'	'	26
Interest paid in cash, net of amounts capitalized	4,678	2,863	77,282
Accretion on redeemable convertible preferred stock	'	'	-952
Issuance of common stock upon conversion of notes payable	'	'	3,331
Increase in additional paid-in capital resulting from merger	'	'	171,154
Issuance of common stock for notes receivable	'	'	2,758
Issuance of common stock pursuant to conversion of facility financing obligation	86,000	'	92,500
Issuance of put option by stockholder	'	'	-2,949
Put option redemption by stockholder	'	'	1,921
Issuance of Series C convertible preferred stock subscriptions	'	'	50,000
Issuance of Series A redeemable convertible preferred stock	'	'	4,296
Conversion of Series A redeemable convertible preferred stock	'	'	-5,248
Non-cash construction in progress and property and equipment	1,700	3,863	1,700
Capitalization of interest on note payable to principal stockholder	'	'	22,105
Reduction of principal on note payable to principal stockholder upon issuance of common stock and exercise of warrants	'	'	290,334
Forward purchase contract contribution to APIC	'	'	29,317
Reclassification of forward purchase contract to APIC	'	'	28,080
Tranche B Commitment Asset	$2,921	'	$2,921

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flows (Parenthetical) (USD $)	277 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Conversion of convertible preferred stock amount converted	$5,248
Series B Preferred Stock	'
Conversion of convertible preferred stock amount converted	15,000
Series C Preferred Stock	'
Conversion of convertible preferred stock amount converted	$50,000

Description_of_business_and_ba

Description of business and basis of presentation	3 Months Ended
	Mar. 31, 2014
Description of business and basis of presentation	'
	1. Description of business and basis of presentation
	The accompanying unaudited condensed consolidated financial statements of MannKind Corporation and its subsidiaries ( “MannKind” or the “Company”), have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The information included in this quarterly report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2013 filed with the SEC on March 3, 2014 (the “Annual Report”).
	In the opinion of management, all adjustments, consisting only of normal, recurring adjustments, considered necessary for a fair presentation of the results of these interim periods have been included. The results of operations for the three months ended March 31, 2014 may not be indicative of the results that may be expected for the full year.
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates or assumptions. The more significant estimates reflected in these accompanying financial statements involve assessing long-lived assets for impairment, accrued expenses, including clinical study expenses, valuation of forward purchase contracts, valuation of the facility financing obligation, commitment asset, milestone rights, valuation of stock-based compensation and the determination of the provision for income taxes and corresponding deferred tax assets and liabilities and any valuation allowance recorded against net deferred tax assets. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.
	Business — The Company is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases such as diabetes. The Company’s lead product candidate, AFREZZA (insulin human [rDNA origin]) inhalation powder, is an ultra rapid-acting insulin therapy that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia.
	Last October, the Company resubmitted a New Drug Application (“NDA”) for AFREZZA to the U.S. Food and Drug Administration (“FDA”), which included data from two completed Phase 3 studies 171 and 175, both of which met their primary efficacy endpoints and safety objectives. On April 1, 2014 the Endocrinologic and Metabolic Drugs Advisory Committee (“EMDA”) of the FDA voted 13 to 1 to recommend that AFREZZA inhalation powder be granted approval by the FDA to improve glycemic control in adults with type 1 diabetes and voted 14 to 0 to recommend that AFREZZA be granted approval by the FDA to improve glycemic control in adults with type 2 diabetes.
	Subsequent to the EMDA meeting, the FDA extended the Prescription Drug User Fee Act (“PDUFA”) date for AFREZZA by three months from April 15, 2014 to July 15, 2014 in order to provide time for a full review of information submitted by the Company in response to the FDA’s requests.
	Basis of Presentation — The Company is considered to be in the development stage as its primary activities since incorporation have been establishing its facilities, recruiting personnel, conducting research and development, business development, business and financial planning, and raising capital. It is costly to develop therapeutic products and conduct clinical studies for these products. From its inception through March 31, 2014, the Company has reported accumulated net losses of $2.3 billion, which include a goodwill impairment charge of $151.4 million and cumulative negative cash flow from operations of $1.8 billion. At March 31, 2014, the Company’s capital resources consisted of cash and cash equivalents of $35.8 million. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.
	As of March 31, 2014, the Company had $30.1 million principal amount of available borrowings under its loan arrangement (the “Loan Arrangement”) with The Mann Group LLC (“The Mann Group”) although the Company anticipates using a portion of these available borrowings to capitalize accrued interest into principal as it becomes due and payable under the Loan Arrangement, upon mutual agreement of the parties. As of March 31, 2014, the Company had accrued $1.3 million of interest related to the Loan Arrangement.
	On July 1, 2013, the Company entered into a facility agreement (the “Facility Agreement”) with Deerfield Private Design Fund II, L.P. (“Deerfield Private Design Fund”) and Deerfield Private Design International II, L.P. (collectively, “Deerfield”), providing for the sale of up to $160.0 million of Senior Convertible Notes due 2019 (the “2019 notes”) to Deerfield in four equal tranches of $40.0 million principal amount. As of March 31, 2014, Deerfield had purchased the first three tranches of 2019 notes in the aggregate principal amount of $120.0 million; therefore, only $40.0 million remain unsold. Deerfield’s obligation to purchase the fourth tranche of 2019 notes is subject to the receipt of marketing approval of AFREZZA by the FDA and the shares of common stock issuable upon conversion of all previously sold 2019 notes being freely tradable pursuant to an effective registration statement filed with the SEC or pursuant to Rule 144 under the Securities Act. On February 28, 2014, the Company entered into a First Amendment to Facility Agreement and Registration Rights Agreement (the “Amendment”). The Amendment modified the terms of the Facility Agreement that was entered into on July 1, 2013 with Deerfield to provide for the issuance of an additional tranche of notes (the “Tranche B notes”) to Deerfield in a maximum principal amount equal to (x) if the FDA approves the NDA for AFREZZA and Deerfield purchased the fourth tranche of 2019 notes, 150% of the aggregate principal amount of the 2019 notes that Deerfield has converted into the Company’s common stock on and after the effective date of the Amendment, up to $90.0 million, and (y) otherwise, 33.33% of the aggregate principal amount of the 2019 notes that Deerfield has converted into the Company’s common stock on and after the effective date of the Amendment, up to $20.0 million, in each case subject to the satisfaction of certain other conditions. The Facility Agreement contains a financial covenant that requires the Company’s cash and cash equivalents, which include available borrowings under the Loan Arrangement, on the last day of each fiscal quarter to not be less than $25 million. Based on its current expectations, the Company believes that its existing capital resources will enable it to continue planned operations at least into the third quarter of 2014. However, the Company cannot provide assurances that its plans will not change or that changed circumstances will not result in the depletion of its capital resources more rapidly than it currently anticipates. The Company will need to raise additional capital, whether through the sale of equity or debt securities, a strategic business collaboration with a pharmaceutical company, the establishment of other funding facilities, licensing arrangements, asset sales or other means, in order to continue the development of and to commercialize AFREZZA and other product candidates and to support its other ongoing activities. However, the Company cannot provide assurances that such additional capital will be available on favorable terms, or at all.
	Capital resources potentially available to the Company include proceeds from the exercise of warrants issued in its February 2012 public offering, the Company’s at-the-market issuance sales agreements, and issuance of additional 2019 notes and/or Tranche B notes to Deerfield (see Note 11 – Facility financing agreement).
	Fair Value of Financial Instruments — The carrying amounts reported in the accompanying financial statements for cash and cash equivalents, accounts payable and accrued liabilities approximate their fair value due to their relatively short maturities. The fair value of the cash equivalents, note payable to related party, senior convertible notes, and the Facility Agreement are discussed in Note 13, “Fair Value Measurements.”
	Recently Issued Accounting Standards — In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force). The amendments in this ASU provide guidance on the financial statements presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. An unrecognized tax benefit should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward with certain exceptions, in which case such an unrecognized tax benefit should be presented in the financial statements as a liability. The amendments in this ASU do not require new recurring disclosures. The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The adoption of the new requirement did not have a significant impact on the Company’s consolidated financial statements.

Accrued_expenses_and_other_cur

Accrued expenses and other current liabilities	3 Months Ended
	Mar. 31, 2014
Accrued expenses and other current liabilities	'
	2. Accrued expenses and other current liabilities
	Accrued expenses and other current liabilities are comprised of the following (in thousands):
		March 31,		December 31,
		2014		2013
	Salary and related expenses	$	6,650	$	12,193
	Research and clinical trial costs		1,304		1,311
	Accrued interest		958		2,082
	Construction in progress		370		342
	Other		5,724		5,706
	Accrued expenses and other current liabilities	$	15,006	$	21,634

Accounting_for_stockbased_comp

Accounting for stock-based compensation	3 Months Ended
	Mar. 31, 2014
Accounting for stock-based compensation	'
	3. Accounting for stock-based compensation
	Total stock-based compensation expense recognized in the accompanying condensed consolidated statements of operations for the three months ended March 31, 2014 and 2013 was as follows (in thousands):
		Three months ended
		March 31,
		2014		2013
	Stock-based compensation	$	10,937	$	5,189
	The Company issued stock awards to employees during the three months ended March 31, 2014 with a four-year vesting schedule. The grant date fair value of the 46,400 restricted stock units and 17,700 stock options issued was $296,000 and $81,000, respectively, with a grant date fair value per share of $6.39 and $4.58, respectively.
	As of March 31, 2014, there was $9.9 million and $14.0 million of unrecognized compensation cost related to options and restricted stock units, respectively, which are expected to be recognized over the remaining weighted average vesting period of 1.85 years. The Company evaluates stock awards with performance conditions as to the probability that the performance conditions will be met and estimates the date at which the performance conditions will be met in order to properly recognize stock-based compensation expense over the requisite service period. As of March 31, 2014, there were $107,000 and $3.7 million of unrecognized expenses related to performance options and restricted stock units, respectively, for milestones not considered probable of achievement.

Net_loss_per_common_share

Net loss per common share	3 Months Ended
	Mar. 31, 2014
Net loss per common share	'
	4. Net loss per common share
	Basic net loss per share excludes dilution for potentially dilutive securities and is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period excluding the shares loaned to Bank of America, N.A. under a share lending arrangement (see Note 7 — Common and preferred stock). As of March 31, 2014, 9,000,000 shares of the Company’s common stock, which were loaned to Bank of America, N.A. pursuant to the terms of a share lending agreement as described in Note 7, were issued and are outstanding, and holders of the borrowed shares have all the rights of a holder of the Company’s common stock. However, because the share borrower must return all borrowed shares to the Company (or, in certain circumstances, the cash value thereof), the borrowed shares are not considered outstanding for the purpose of computing and reporting basic or diluted earnings (loss) per share. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Potentially dilutive securities are excluded from the computation of diluted net loss per share for all of the periods presented in the accompanying condensed consolidated statements of operations because the reported net loss in each of these periods results in their inclusion being antidilutive. Antidilutive securities, which consist of stock options, restricted stock units, warrants, and shares that could be issued upon conversion of the senior convertible notes and conversion of the facility financing obligation, that are not included in the diluted net loss per share calculation consisted of an aggregate of 67,791,150 shares and 133,500,568 shares as of March 31, 2014 and 2013, respectively, and exclude the 9,000,000 shares loaned under the share lending arrangement.

State_research_and_development

State research and development credit exchange receivable	3 Months Ended
	Mar. 31, 2014
State research and development credit exchange receivable	'
	5. State research and development credit exchange receivable
	The State of Connecticut provides certain companies with the opportunity to exchange certain research and development income tax credit carryforwards for cash in exchange for forgoing the carryforward of the research and development income tax credits. The program provides for an exchange of research and development income tax credits for cash equal to 65% of the value of corporation tax credit available for exchange. There were no current estimated amounts receivable under the program at March 31, 2014 and December 31, 2013, respectively. Long-term estimated amounts receivable under the program were $380,000 and $298,000 at March 31, 2014 and December 31, 2013, respectively.

Property_and_equipment

Property and equipment	3 Months Ended
	Mar. 31, 2014
Property and equipment	'
	6. Property and equipment
	Property and equipment — net consist of the following (dollar amounts in thousands):
		Estimated		March 31,			December 31,
		Useful		2014			2013
		Life
		(Years)
	Land		—	$	5,273		$	5,273
	Buildings		39-40		54,948			54,948
	Building improvements		May-40		114,099			114,099
	Machinery and equipment		15-Mar		82,189			82,189
	Furniture, fixtures and office equipment		10-May		5,046			5,046
	Computer equipment and software		3		11,306			11,289
	Leasehold improvements		4		17			17
	Construction in progress				17,041			14,756
					289,919			287,617
	Less accumulated depreciation and amortization				(113,582	)		(111,060	)
	Property and equipment — net			$	176,337		$	176,557
	Leasehold improvements are amortized over four years which is the shorter of the term of the lease or the service lives of the improvements.
	Depreciation and amortization expense related to property and equipment for the three months ended March 31, 2014 and 2013 was as follows (in thousands):
		Three months ended
		March 31,
		2014		2013
	Depreciation and amortization expense	$	2,522	$	2,990

Common_and_preferred_stock

Common and preferred stock	3 Months Ended
	Mar. 31, 2014
Common and preferred stock	'
	7. Common and preferred stock
	The Company is authorized to issue 550,000,000 shares of common stock, par value $0.01 per share, and 10,000,000 shares of undesignated preferred stock, par value $0.01 per share, issuable in one or more series designated by the Company’s board of directors. No other class of capital stock is authorized. As of March 31, 2014 and December 31, 2013, 386,934,914 and 369,391,972 shares of common stock, respectively, were issued and outstanding and no shares of preferred stock were outstanding. Included in the common stock outstanding as of March 31, 2014 and December 31, 2013 are 9,000,000 shares of common stock loaned to Bank of America under a share lending agreement in connection with the offering of $100.0 million aggregate principal amount of 2015 notes (see Note 10 — Senior convertible notes). Bank of America is obligated to return the borrowed shares (or, in certain circumstances, the cash value thereof) to the Company on or about the 45th business day following the date as of which the entire principal amount of the 2015 notes ceases to be outstanding, subject to extension or acceleration in certain circumstances or early termination at Bank of America’s option. The Company did not receive any proceeds from the sale of the borrowed shares by Bank of America, but the Company did receive a nominal lending fee of $0.01 per share from Bank of America for the use of borrowed shares.
	On July 1, 2013, the Company entered into the Facility Agreement with Deerfield providing for the sale of up to $160.0 million of 2019 notes to Deerfield in four equal tranches of $40.0 million principal amount. A portion of the principal amount of the 2019 notes were convertible into shares of the Company’s common stock at the note holder’s option.
	On February 28, 2014, the Company amended the Facility Agreement to, among other things, allow Deerfield, subject to certain limitations, to convert up to an additional $60.0 million principal amount under the then-outstanding 2019 notes into common stock after the effective date of the Amendment, at a minimum conversion price of $5.00 per share unless the Company otherwise consents. The Company also agreed to register for resale up to 12,000,000 shares of common stock issuable upon conversion of the outstanding 2019 notes, with a minimum conversion price of $5.00 per share unless the Company otherwise consents. The conversion price will be determined by the average of the volume weighted average prices per share during the three trading days immediately preceding the election to convert. As of March 31, 2014, Deerfield had converted a portion of the outstanding 2019 notes into common stock (see Note 11 – Facility financing agreement).

Commitments_and_contingencies

Commitments and contingencies	3 Months Ended
	Mar. 31, 2014
Commitments and contingencies	'
	8. Commitments and contingencies
	Guarantees and Indemnifications — In the ordinary course of its business, the Company makes certain indemnities, commitments and guarantees under which it may be required to make payments in relation to certain transactions. The Company, as permitted under Delaware law and in accordance with its Bylaws, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that may enable it to recover a portion of any future amounts paid. The Company believes the fair value of these indemnification agreements is minimal. The Company has not recorded any liability for these indemnities in the accompanying condensed consolidated balance sheets. However, the Company accrues for losses for any known contingent liability, including those that may arise from indemnification provisions, when future payment is probable and the amount can be reasonably estimated.
	Litigation — The Company is subject to legal proceedings and claims which arise in the ordinary course of its business. As of the date hereof, the Company believes that the final disposition of such matters will not have a material adverse effect on the financial position, results of operations or cash flows of the Company. The Company maintains liability insurance coverage to protect the Company’s assets from losses arising out of or involving activities associated with ongoing and normal business operations. In accordance with ASC 450 Contingencies, the Company would record a provision for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.
	Contingencies — In connection with the Facility Agreement, on July 1, 2013 the Company also entered into a Milestone Rights Purchase Agreement (the “Milestone Agreement”) with Deerfield Private Design Fund and Horizon Santé FLML SÁRL (collectively, the “Milestone Purchasers”), pursuant to which the Company sold the Milestone Purchasers certain rights (the “Milestone Rights”) to receive payments of up to $90.0 million upon the occurrence of specified strategic and sales milestones, including the first commercial sale of an AFREZZA product and the achievement of specified net sales figures (see Note 11 – Facility financing agreement).

Relatedparty_arrangements

Related-party arrangements	3 Months Ended
	Mar. 31, 2014
Related-party arrangements	'
	9. Related-party arrangements
	In October 2007, the Company entered into a $350.0 million loan arrangement with its principal stockholder. The Loan Arrangement has been amended from time to time. On October 31, 2013, the promissory note underlying the Loan Arrangement was amended to, among other things, extend the maturity date of the loan to January 5, 2020, extend the date through which the Company can borrow under the Loan Arrangement to December 31, 2019, increase the aggregate borrowing amount under the Loan Arrangement from $350.0 million to $370.0 million and provide that repayments or cancellations of principal under the Loan Arrangement will not be available for reborrowing.
	As of March 31, 2014, the total principal amount outstanding under the Loan Arrangement was $49.5 million, and the amount available for future borrowings was $30.1 million. Interest, at a fixed rate of 5.84%, is due and payable quarterly in arrears on the first day of each calendar quarter for the preceding quarter, or at such other time as the Company and The Mann Group mutually agree. All or any portion of accrued and unpaid interest that becomes due and payable may be paid-in-kind and capitalized as additional borrowings at any time and would be classified as non-current upon mutual agreement of both parties. As of March 31, 2014, the Company had accrued $1.3 million of interest in other liabilities related to the Loan Arrangement. The Mann Group can require the Company to prepay up to $200.0 million in advances that have been outstanding for at least 12 months (less approximately $105.0 million aggregate principal amount that has been cancelled in connection with two common stock purchase agreements). If The Mann Group exercises this right, the Company will have 90 days after The Mann Group provides written notice (or the number of days to maturity of the note if less than 90 days) to prepay such advances. However, pursuant to a letter agreement entered into in August 2010, The Mann Group has agreed to not require the Company to prepay amounts outstanding under the amended and restated promissory note if the prepayment would require the Company to use its working capital resources. In addition, The Mann Group entered into a subordination agreement with Deerfield pursuant to which The Mann Group agreed with Deerfield not to demand or accept any payment under the Loan Arrangement until the Company’s payment obligations to Deerfield under the Facility Agreement have been satisfied in full. Subject to the foregoing, in the event of a default under the Loan Arrangement, all unpaid principal and interest either becomes immediately due and payable or may be accelerated at The Mann Group’s option, and the interest rate will increase to the one-year LIBOR calculated on the date of the initial advance or in effect on the date of default, whichever is greater, plus 5% per annum. All borrowings under the Loan Arrangement are unsecured. The Loan Arrangement contains no financial covenants.
	During the first quarter of 2014, there were no borrowings under or amendments to the Loan Arrangement.

Senior_convertible_notes

Senior convertible notes	3 Months Ended
	Mar. 31, 2014
Senior convertible notes	'
	10. Senior convertible notes
	Senior convertible notes consist of the following (in thousands):
		March 31,			December 31,
		2014			2013
	2015 notes
	Principal amount	$	100,000		$	100,000
	Unaccreted debt issuance expense		(1,338	)		(1,561	)
	Net carrying amount	$	98,662		$	98,439
	On August 18, 2010, the Company completed a Rule 144A offering of $100.0 million aggregate principal amount of 5.75% Senior Convertible Notes due 2015 (the “2015 notes”). The 2015 notes are governed by the terms of an indenture dated as of August 24, 2010 (the “2015 Note Indenture”). The 2015 notes bear interest at the rate of 5.75% per year on the principal amount, payable in cash semi-annually in arrears on February 15 and August 15 of each year, beginning February 15, 2011. In connection with the 2015 notes, the Company had accrued interest of $1.0 million and $2.4 million as of March 31, 2014 and December 31, 2013, respectively. The 2015 notes are general, unsecured, senior obligations of the Company and effectively rank junior in right of payment to all of the Company’s secured debt, to the extent of the value of the assets securing such debt, and to the debt and all other liabilities of the Company’s subsidiaries. The maturity date of the 2015 notes is August 15, 2015 and payment is due in full on that date for unconverted securities. Holders of the 2015 notes may convert, at any time prior to the close of business on the business day immediately preceding the stated maturity date, any outstanding principal into shares of the Company’s common stock at an initial conversion rate of 147.0859 shares per $1,000 principal amount, which is equal to a conversion price of approximately $6.80 per share, subject to adjustment. Except in certain circumstances, if the Company undergoes a fundamental change: (1) the Company will pay a make-whole premium on the 2015 notes converted in connection with a fundamental change by increasing the conversion rate on such 2015 notes, which amount, if any, will be based on the Company’s common stock price and the effective date of the fundamental change, and (2) each holder of 2015 notes will have the option to require the Company to repurchase all or any portion of such holder’s 2015 notes at a repurchase price of 100% of the principal amount of the 2015 notes to be repurchased plus accrued and unpaid interest, if any. The Company may elect to redeem some or all of the 2015 notes if the closing stock price has equaled 150% of the conversion price for at least 20 of the 30 consecutive trading days ending on the trading day before the Company’s redemption notice. The redemption price will equal 100% of the principal amount of the 2015 notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date, plus a make-whole payment equal to the sum of the present values of the remaining scheduled interest payments through and including August 15, 2015 (other than interest accrued up to, but excluding, the redemption date). The Company will be obligated to make the make-whole payment on all the 2015 notes called for redemption and converted during the period from the date the Company mailed the notice of redemption to and including the redemption date. The Company may elect to make the make-whole payment in cash or shares of its common stock, subject to certain limitations. Under the terms of the 2015 Note Indenture, the conversion option can be net-share settled and the maximum number of shares that could be required to be delivered under the contract, including the make-whole shares, is fixed and less than the number of authorized and unissued shares less the maximum number of shares that could be required to be delivered during the contract period under existing commitments. Applying the Company’s sequencing policy, the Company performed an analysis at the time of the offering of the 2015 notes and each reporting date since and has concluded that the number of available authorized shares at the time of the offering and each subsequent reporting date was sufficient to deliver the number of shares that could be required to be delivered during the contract period under existing commitments.
	The Company incurred approximately $4.2 million in issuance costs which are recorded as an offset to the 2015 notes in the accompanying condensed consolidated balance sheets. These costs are being accreted to interest expense using the effective interest method over the term of the 2015 notes.
	The 2015 notes provide that upon an acceleration of certain indebtedness, which would include the 2019 notes or the Tranche B notes described in Note 11, the holders may elect to accelerate the Company’s repayment obligations under the notes if such acceleration is not cured, waived, rescinded or annulled. There can be no assurance that the holders would not choose to exercise these rights in the event such events were to occur.
	Accretion of debt issuance expense in connection with the 2015 notes during the three months ended March 31, 2014 and 2013 was $223,000 and $209,000, respectively.

Facility_financing_agreement

Facility financing agreement	3 Months Ended
	Mar. 31, 2014
Facility financing agreement	'
	11. Facility financing agreement
	The components and activity from initial recording of the facility financing agreement recorded through March 31, 2014 consist of the following (in thousands):
		March 31,
		2014
	2019 notes
	Initial principal amount	$	120,000
	Principal converted to equity		(92,500	)
	Debt discount-net of amortization		(1,546	)
	Unaccreted debt issuance expense		(83	)
	Net carrying amount of facility financing agreement	$	25,871
	Milestone Rights
	Initial milestone rights fair value	$	16,276
	Debt discount-net of amortization		(51	)
	Unaccreted debt issuance expense		(61	)
	Less current portion of milestone rights included in other current liabilities		(3,151	)
	Net carrying amount included in other liabilities	$	13,013
	Commitment Asset
	Initial commitment asset fair value	$	13,393
	Tranche B commitment asset fair value	$	2,921
	Less Tranche 2 portion of commitment asset		(3,656	)
	Less Tranche 3 portion of commitment asset		(4,580	)
	Commitment asset value included in other assets	$	8,078
	Accretion of debt issuance cost and debt discount in connection with the Facility financing agreement during the three months ended March 31, 2014 are as follows (in thousands):
		Three months ended
		March 31, 2014
	Accretion expense- debt issuance cost	$	282
	Accretion expense- debt discount	$	6,367
	On July 1, 2013, the Company entered into the Facility Agreement providing for the sale of up to $160.0 million of 2019 notes to Deerfield in four equal tranches of $40.0 million principal amount. The 2019 notes accrue interest at a rate of 9.75% per annum until maturity in 2019 or their earlier repayment, repurchase, or conversion. As of March 31, 2014, Deerfield had purchased the first three tranches of 2019 notes in the aggregate principal amount of $120.0 million; therefore, only $40.0 million remain unsold. Deerfield’s obligation to purchase the fourth tranche of 2019 notes is subject to receipt of marketing approval of AFREZZA by the FDA and the shares of common stock issuable upon conversion of all previously sold 2019 notes being freely tradable pursuant to an effective registration statement filed with the SEC or pursuant to Rule 144 under the Securities Act.
	On February 28, 2014, the Company entered into the Amendment, which modified the terms of the Facility Agreement to provide for the issuance of Tranche B notes to Deerfield in a maximum principal amount equal to (i) if the FDA approves the NDA for AFREZZA and Deerfield purchased the fourth tranche of 2019 notes, 150% of the aggregate principal amount of the 2019 notes that Deerfield has converted into the Company’s common stock on and after the effective date of the Amendment, up to $90.0 million, and (ii) otherwise, 33.33% of the aggregate principal amount of the 2019 notes that Deerfield has converted into the Company’s common stock on and after the effective date of the Amendment, up to $20.0 million, in each case subject to the satisfaction of certain other conditions. The Tranche B notes bear interest at the rate of 9.75% per year, subject to reduction to 8.75% if the Company enters into a collaboration with a third party to commercialize AFREZZA, on the outstanding principal amount, payable in cash quarterly in arrears on the last business day of March, June, September and December of each year. The Company is required to repay 25% of the original principal amount of any Tranche B notes on the third, fourth, fifth and sixth anniversaries of the applicable issue dates of such notes, provided that the entire outstanding principal amount of all Tranche B notes will become due and payable no later than December 31, 2019. The Tranche B notes can be prepaid without penalty or premium commencing two years after issuance thereof.
	In addition, pursuant to the Amendment, the outstanding first tranche of 2019 notes (the “Tranche 1 notes”) and third tranche of 2019 notes (the “Tranche 3 notes”) held by Deerfield were amended and restated such that Deerfield may, subject to certain limitations, convert up to an additional $60.0 million principal amount under such 2019 notes into common stock after the effective date of the Amendment, at a minimum conversion price of $5.00 per share. The Company also agreed to register for resale up to 12,000,000 shares of common stock issuable upon conversion of the outstanding 2019 notes, as amended and restated, as of the date of the Amendment.
	Commitment Asset
	In connection with the issuance of the Tranche 1 notes and the Milestone Rights, the Company recorded a commitment asset, or the Commitment Asset, on July 1, 2013. As a result of the Amendment, the Company recorded an additional commitment asset with an estimated fair value equal to $2.9 million. The Commitment Asset remaining as of March 31, 2014 represents the right to receive $40.0 million funding under tranche 4 of 2019 notes and up to $90 million of funding under Tranche B notes, subject to the achievement of certain milestones, pursuant to the Facility Agreement, as amended. The Commitment Asset is derecognized and recorded as a debt discount on the 2019 notes and Tranche B notes when issued and amortized using the effective interest rate method over the life of the notes. Prior to derecognition occurring, the Company monitors the Commitment Asset on an ongoing basis to determine whether an impairment indicator is present that would result in a full or partial write down of the Commitment Asset as a result of events that may lead to the subsequent tranches of notes not being issued. Based on the monitoring procedures performed through March 31, 2014, the Company did not identify any indicators of impairment.
	Amendment to the outstanding Tranche 1 and Tranche 3 notes
	The amendment and restatement of the outstanding Tranche 1 and Tranche 3 notes, pursuant to the Amendment, did not represent a troubled debt restructuring in the notes because the Amendment did not result in Deerfield granting a concession to the Company. In addition, the Amendment did not result in a substantial modification to the terms of the Tranche 1 and Tranche 3 notes.
	The impact of the Amendment to the Tranche 1 and Tranche 3 notes will be accounted for as a prospective yield adjustment. Specifically the value of the Tranche B Commitment Asset was considered a fee received from the creditor as consideration for the Amendment and will be amortized as an adjustment of interest expense over the remaining term of the Tranche 1 and Tranche 3 notes using the effective interest method. As a result of the Amendment, the value of the Tranche B Commitment Asset was allocated between the Tranche 1 and Tranche 3 notes, which decreased the amount of debt discount on the Tranche 1 and Tranche 3 notes.
	Conversion Option
	For accounting purposes, the Company evaluated the embedded conversion option in the 2019 notes as a redemption feature because the number of shares issuable upon conversion is based on the volume weighted average prices for specified periods prior to the conversion date (as opposed to being fixed). Accordingly, conversions by Deerfield were treated as redemptions of the 2019 notes and, as discussed below, the Company analyzed whether the conversion option required bifurcation as an embedded redemption feature. As of December 31, 2013, Deerfield had converted $6.5 million principal amount of the second tranche of 2019 notes (the “Tranche 2 notes”) for equity, resulting in an issuance of 1,293,224 shares of the Company’s common stock. Upon the conversion, the principal balance of the notes were recorded in equity and an expense was recognized in the Statement of Operations in the amount of $0.6 million for the difference between the principal amount of the notes converted and their carrying amount (which included unamortized discount and debt issuance costs).
	During January 2014, Deerfield elected to convert the remaining $33.5 million of Tranche 2 notes, which resulted in the issuance of 6,559,251 shares of the Company’s common stock. During the three months ended March 31, 2014, the Company recorded an expense of $3.0 million for the difference between the principal amount of the notes converted and their carrying amount (which included unamortized discount and debt issuance costs).
	In March 2014, following the Amendment, which allowed Deerfield to convert up to an additional $60 million principal amount under the outstanding Tranche 1 and Tranche 3 notes, Deerfield elected to convert the full $40.0 million of outstanding principal amount of the Tranche 3 notes and $12.5 million of principal amount of the Tranche 1 notes, pursuant to which the Company issued Deerfield 7,121,120 and 2,142,709 shares of the Company’s common stock, respectively. As a result of these conversions, the Company recorded the principal balance of the notes in equity and an expense of $3.0 million for the difference between the principal amount of the notes converted and their carrying amount (which included the unamortized discount and debt issuance costs) and the write-off of the derivative liability that was previously bifurcated from the Tranche 3 notes.
	In addition, the Company considered whether the amendment to the 2019 notes would result in the bifurcation of the conversion option in the Tranche 1 notes. Upon the issuance of the Tranche 1 notes on July 1, 2013 and as of March 31, 2014, the Company concluded that the conversion option was not required to be separated primarily due to the discount in the Tranche 1 notes not being deemed substantial under ASC 815-15-25-26.

Income_taxes

Income taxes	3 Months Ended
	Mar. 31, 2014
Income taxes	'
	12. Income taxes
	As required by ASC 740 Income Taxes (“ASC 740”), management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets and concluded, in accordance with the applicable accounting standards, that net deferred tax assets should be fully reserved.
	ASC 740-10-25 Income Taxes Recognition clarifies the accounting and disclosure for uncertainty in tax positions, as defined. This guidance seeks to reduce the diversity in practice associated with certain aspects of the recognition and measurement related to accounting for income taxes. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded pursuant to this guidance. Tax years since 1993 remain subject to examination by the major tax jurisdictions in which the Company is subject to tax.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2014
Fair Value of Financial Instruments	'
	13. Fair Value of Financial Instruments
	The Company applies various valuation approaches in determining the fair value of its financial assets and liabilities within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:
	Level 1— Quoted prices for identical instruments in active markets.
	Level 2— Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.
	Level 3— Significant inputs to the valuation model are unobservable.
	The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level input that is significant to the overall fair value measurement.
	Cash and cash equivalents
	Cash equivalents consist of highly liquid investments with original or remaining maturities of 90 days or less at the time of purchase, that are readily convertible into cash. As of March 31, 2014 and December 31, 2013, the Company held $35.8 million and $70.8 million, respectively, of cash and cash equivalents, consisting primarily of money market funds of $34.9 million and $67.7 million, respectively, and the remaining in non-interest bearing checking accounts. The fair value of these money market funds was determined by using quoted prices for identical investments in an active market (Level 1 in the fair value hierarchy).
	The following is a summary of the carrying values and estimated fair values of the Company’s 5.75% Senior Convertible Notes due 2015 (the “2015 notes”) and the 2019 notes (in millions).
		March 31, 2014				December 31, 2013
		Carrying		Estimated		Carrying		Estimated
		value		fair value		value		fair value
	2015 notes	$	98.7	$	95.1	$	98.4	$	102.2
	2019 notes	$	25.9	$	25.7	$	102.3	$	107
	Senior Convertible Notes
	The estimated fair value of the 2015 notes was calculated based on model-derived valuations whose inputs were observable, such as the Company’s stock price, and non-observable, such as the Company’s longer-term historical volatility (Level 3 in the fair value hierarchy). As there is no current observable market for the 2015 notes, the Company determined the estimated fair value using a convertible bond valuation model within a lattice framework. The convertible bond valuation model combined expected cash outflows with market-based assumptions regarding risk-adjusted yields, stock price volatility and recent price quotes and trading information regarding Company issued debt instruments and shares of common stock into which the notes are convertible.
	Facility financing agreement
	As discussed in Note 11 — Facility financing agreement, in connection with the Facility Agreement, the Company issued 2019 notes and Milestone Rights and recorded the Commitment Asset on July 1, 2013. As there is no current observable market for the 2019 notes, the Company determined the estimated fair value using a bond valuation model based on a discounted cash flow methodology. The bond valuation model combined expected cash flows associated with principal repayment and interest based on the contractual terms of the debt agreement discounted to present value using a selected market discount rate of 12.7% (Level 3 in the fair value hierarchy). On March 31, 2014, the market discount rate was recalculated at 12.5% for the Tranche 1 notes. The Tranche 2 and Tranche 3 notes were fully converted by the end of the first quarter.
	The estimated fair value of the Milestone Rights was calculated using the income approach in which the cash flows associated with the specified contractual payments were adjusted for both the expected timing and the probability of achieving the milestones discounted to present value using a selected market discount rate (Level 3 in the fair value hierarchy). The expected timing and probability of achieving the milestones, starting in 2014, was developed with consideration given to both internal data, such as progress made to date and assessment of criteria required for achievement, and external data, such as market research studies. The discount rate (17.5%) was selected based on an estimation of required rate of returns for similar investment opportunities using available market data.
	The fair value of the Commitment Asset was estimated using the income approach by estimating the fair value of the future tranches using a market debt rate (12%) commensurate with the risk of the future tranches and the fair value of the cash expected to be received by the Company and assessing the probability of the commitments being funded in the future based on the operational hurdles required for funding being met (Level 3 in the fair value hierarchy).
	At March 31, 2014, as there had been no material changes to the established estimates, the carrying value of the Milestone Rights and Commitment Asset approximates their respective estimated fair values.
	Also as discussed in Note 11 – Facility financing agreement, on February 28, 2014, the Company entered into the Amendment to Facility Agreement, and recorded an additional commitment asset which represented the increase in borrowing capacity that the Company received as consideration for the modifications made to the Facility Agreement and the Tranche 1 notes and Tranche 3 notes. The fair value of the additional commitment asset was estimated using a discounted cash flow analysis under the income approach. Specifically, the fair value of the additional commitment asset was determined by estimating the fair value of the future tranche using a market yield (11.9%) commensurate with the risk of the future tranche and the fair value of the cash expected to be received by the Company and assessing the probability of the commitment being funded in the future based on the operational hurdles required for funding being met as well as consideration of alternative funding options (Level 3 in the fair value hierarchy). As of February 28, 2014, the additional commitment asset was valued at $2.9 million. At March 31, 2014, as there have been no material changes to the established estimates, the carrying value of the Tranche B Commitment Asset approximates its respective estimated fair values.
	There were no material re-measurements to fair value during the three months ended March 31, 2014 and 2013 of financial assets and liabilities that are not measured at fair value on a recurring basis. There were no transfers of assets or liabilities between the fair value measurement levels during the three months ended March 31, 2014 and 2013.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2014
Subsequent Events	'
	14. Subsequent Events
	On April 1, 2014 the EMDA voted 13 to 1 to recommend that AFREZZA inhalation powder be granted approval by the FDA to improve glycemic control in adults with type 1 diabetes and voted 14 to 0 to recommend that AFREZZA be granted approval by the FDA to improve glycemic control in adults with type 2 diabetes.
	Subsequent to the EMDA meeting, the FDA extended the PDUFA date for AFREZZA by three months from April 15, 2014 to July 15, 2014 in order to provide time for a full review of information submitted by MannKind in response to the FDA’s requests.
	On April 2, 2014, Deerfield elected to convert an aggregate of $7.5 million of principal amount of the Tranche 1 notes, pursuant to which the Company issued Deerfield 1,500,000 shares of the Company’s common stock. As a result of this election, Deerfield has fully exercised the conversion option under the Amendment by converting the additional $60.0 million of the Tranche 1 and Tranche 3 notes allowable, into 10,763,829 shares of the Company’s common stock in the aggregate.
	On May 6, 2014, Deerfield purchased an aggregate principal amount of $20.0 million in Tranche B notes in accordance with the provisions of the Facility Agreement, as amended.

Description_of_business_and_ba1

Description of business and basis of presentation (Policies)	3 Months Ended
	Mar. 31, 2014
Business	'
	Business — The Company is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases such as diabetes. The Company’s lead product candidate, AFREZZA (insulin human [rDNA origin]) inhalation powder, is an ultra rapid-acting insulin therapy that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia.
	Last October, the Company resubmitted a New Drug Application (“NDA”) for AFREZZA to the U.S. Food and Drug Administration (“FDA”), which included data from two completed Phase 3 studies 171 and 175, both of which met their primary efficacy endpoints and safety objectives. On April 1, 2014 the Endocrinologic and Metabolic Drugs Advisory Committee (“EMDA”) of the FDA voted 13 to 1 to recommend that AFREZZA inhalation powder be granted approval by the FDA to improve glycemic control in adults with type 1 diabetes and voted 14 to 0 to recommend that AFREZZA be granted approval by the FDA to improve glycemic control in adults with type 2 diabetes.
	Subsequent to the EMDA meeting, the FDA extended the Prescription Drug User Fee Act (“PDUFA”) date for AFREZZA by three months from April 15, 2014 to July 15, 2014 in order to provide time for a full review of information submitted by the Company in response to the FDA’s requests.
Basis of Presentation	'
	Basis of Presentation — The Company is considered to be in the development stage as its primary activities since incorporation have been establishing its facilities, recruiting personnel, conducting research and development, business development, business and financial planning, and raising capital. It is costly to develop therapeutic products and conduct clinical studies for these products. From its inception through March 31, 2014, the Company has reported accumulated net losses of $2.3 billion, which include a goodwill impairment charge of $151.4 million and cumulative negative cash flow from operations of $1.8 billion. At March 31, 2014, the Company’s capital resources consisted of cash and cash equivalents of $35.8 million. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.
	As of March 31, 2014, the Company had $30.1 million principal amount of available borrowings under its loan arrangement (the “Loan Arrangement”) with The Mann Group LLC (“The Mann Group”) although the Company anticipates using a portion of these available borrowings to capitalize accrued interest into principal as it becomes due and payable under the Loan Arrangement, upon mutual agreement of the parties. As of March 31, 2014, the Company had accrued $1.3 million of interest related to the Loan Arrangement.
	On July 1, 2013, the Company entered into a facility agreement (the “Facility Agreement”) with Deerfield Private Design Fund II, L.P. (“Deerfield Private Design Fund”) and Deerfield Private Design International II, L.P. (collectively, “Deerfield”), providing for the sale of up to $160.0 million of Senior Convertible Notes due 2019 (the “2019 notes”) to Deerfield in four equal tranches of $40.0 million principal amount. As of March 31, 2014, Deerfield had purchased the first three tranches of 2019 notes in the aggregate principal amount of $120.0 million; therefore, only $40.0 million remain unsold. Deerfield’s obligation to purchase the fourth tranche of 2019 notes is subject to the receipt of marketing approval of AFREZZA by the FDA and the shares of common stock issuable upon conversion of all previously sold 2019 notes being freely tradable pursuant to an effective registration statement filed with the SEC or pursuant to Rule 144 under the Securities Act. On February 28, 2014, the Company entered into a First Amendment to Facility Agreement and Registration Rights Agreement (the “Amendment”). The Amendment modified the terms of the Facility Agreement that was entered into on July 1, 2013 with Deerfield to provide for the issuance of an additional tranche of notes (the “Tranche B notes”) to Deerfield in a maximum principal amount equal to (x) if the FDA approves the NDA for AFFREZZA and Deerfield purchased the fourth tranche of 2019 notes, 150% of the aggregate principal amount of the 2019 notes that Deerfield has converted into the Company’s common stock on and after the effective date of the Amendment, up to $90.0 million, and (y) otherwise, 33.33% of the aggregate principal amount of the 2019 notes that Deerfield has converted into the Company’s common stock on and after the effective date of the Amendment, up to $20.0 million, in each case subject to the satisfaction of certain other conditions. The Facility Agreement contains a financial covenant that requires the Company’s cash and cash equivalents, which include available borrowings under the Loan Arrangement, on the last day of each fiscal quarter to not be less than $25 million. Based on its current expectations, the Company believes that its existing capital resources will enable it to continue planned operations at least into the third quarter of 2014. However, the Company cannot provide assurances that its plans will not change or that changed circumstances will not result in the depletion of its capital resources more rapidly than it currently anticipates. The Company will need to raise additional capital, whether through the sale of equity or debt securities, a strategic business collaboration with a pharmaceutical company, the establishment of other funding facilities, licensing arrangements, asset sales or other means, in order to continue the development of and to commercialize AFREZZA and other product candidates and to support its other ongoing activities. However, the Company cannot provide assurances that such additional capital will be available on favorable terms, or at all.
	Capital resources potentially available to the Company include proceeds from the exercise of warrants issued in its February 2012 public offering, the Company’s at-the-market issuance sales agreements, and issuance of additional 2019 notes and/or Tranche B notes to Deerfield (see Note 11 – Facility financing agreement).
Fair Value of Financial Instruments	'Fair Value of Financial Instruments — The carrying amounts reported in the accompanying financial statements for cash and cash equivalents, accounts payable and accrued liabilities approximate their fair value due to their relatively short maturities. The fair value of the cash equivalents, note payable to related party, senior convertible notes, and the Facility Agreement are discussed in Note 13, “Fair Value Measurements.”
Recently Issued Accounting Standards	'
	Recently Issued Accounting Standards — In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force). The amendments in this ASU provide guidance on the financial statements presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. An unrecognized tax benefit should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward with certain exceptions, in which case such an unrecognized tax benefit should be presented in the financial statements as a liability. The amendments in this ASU do not require new recurring disclosures. The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The adoption of the new requirement did not have a significant impact on the Company’s consolidated financial statements.

Accrued_expenses_and_other_cur1

Accrued expenses and other current liabilities (Tables)	3 Months Ended
	Mar. 31, 2014
Accrued Expenses and Other Current Liabilities	'
	Accrued expenses and other current liabilities are comprised of the following (in thousands):
		March 31,		December 31,
		2014		2013
	Salary and related expenses	$	6,650	$	12,193
	Research and clinical trial costs		1,304		1,311
	Accrued interest		958		2,082
	Construction in progress		370		342
	Other		5,724		5,706
	Accrued expenses and other current liabilities	$	15,006	$	21,634

Accounting_for_stockbased_comp1

Accounting for stock-based compensation (Tables)	3 Months Ended
	Mar. 31, 2014
Stock-Based Compensation Expense Recognized in Condensed Consolidated Statements of Operations	'
	Total stock-based compensation expense recognized in the accompanying condensed consolidated statements of operations for the three months ended March 31, 2014 and 2013 was as follows (in thousands):
		Three months ended
		March 31,
		2014		2013
	Stock-based compensation	$	10,937	$	5,189

Property_and_equipment_Tables

Property and equipment (Tables)	3 Months Ended
	Mar. 31, 2014
Property and Equipment	'
	Property and equipment — net consist of the following (dollar amounts in thousands):
		Estimated		March 31,			December 31,
		Useful		2014			2013
		Life
		(Years)
	Land		—	$	5,273		$	5,273
	Buildings		39-40		54,948			54,948
	Building improvements		May-40		114,099			114,099
	Machinery and equipment		15-Mar		82,189			82,189
	Furniture, fixtures and office equipment		10-May		5,046			5,046
	Computer equipment and software		3		11,306			11,289
	Leasehold improvements		4		17			17
	Construction in progress				17,041			14,756
					289,919			287,617
	Less accumulated depreciation and amortization				(113,582	)		(111,060	)
	Property and equipment — net			$	176,337		$	176,557
Depreciation and Amortization Expense	'
	Depreciation and amortization expense related to property and equipment for the three months ended March 31, 2014 and 2013 was as follows (in thousands):
		Three months ended
		March 31,
		2014		2013
	Depreciation and amortization expense	$	2,522	$	2,990

Senior_convertible_notes_Table

Senior convertible notes (Tables)	3 Months Ended
	Mar. 31, 2014
Summary of Senior Convertible Notes	'
	Senior convertible notes consist of the following (in thousands):
		March 31,			December 31,
		2014			2013
	2015 notes
	Principal amount	$	100,000		$	100,000
	Unaccreted debt issuance expense		(1,338	)		(1,561	)
	Net carrying amount	$	98,662		$	98,439

Facility_financing_agreement_T

Facility financing agreement (Tables)	3 Months Ended
	Mar. 31, 2014
Components and Activity of Facility Agreement	'
	The components and activity from initial recording of the facility financing agreement recorded through March 31, 2014 consist of the following (in thousands):
		March 31,
		2014
	2019 notes
	Initial principal amount	$	120,000
	Principal converted to equity		(92,500	)
	Debt discount-net of amortization		(1,546	)
	Unaccreted debt issuance expense		(83	)
	Net carrying amount of facility financing agreement	$	25,871
	Milestone Rights
	Initial milestone rights fair value	$	16,276
	Debt discount-net of amortization		(51	)
	Unaccreted debt issuance expense		(61	)
	Less current portion of milestone rights included in other current liabilities		(3,151	)
	Net carrying amount included in other liabilities	$	13,013
	Commitment Asset
	Initial commitment asset fair value	$	13,393
	Tranche B commitment asset fair value	$	2,921
	Less Tranche 2 portion of commitment asset		(3,656	)
	Less Tranche 3 portion of commitment asset		(4,580	)
	Commitment asset value included in other assets	$	8,078
Accretion of Debt Issuance Cost and Debt Discount	'
	Accretion of debt issuance cost and debt discount in connection with the Facility financing agreement during the three months ended March 31, 2014 are as follows (in thousands):
		Three months ended
		March 31, 2014
	Accretion expense- debt issuance cost	$	282
	Accretion expense- debt discount	$	6,367

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2014
Summary of Carrying Values and Estimated Fair Values of Senior Convertible Notes and Facility Financing Obligation	'
	The following is a summary of the carrying values and estimated fair values of the Company’s 5.75% Senior Convertible Notes due 2015 (the “2015 notes”) and the 2019 notes (in millions).
		March 31, 2014				December 31, 2013
		Carrying		Estimated		Carrying		Estimated
		value		fair value		value		fair value
	2015 notes	$	98.7	$	95.1	$	98.4	$	102.2
	2019 notes	$	25.9	$	25.7	$	102.3	$	107

Recovered_Sheet1

Description of Business and Basis of Presentation - Additional Information (Detail) (USD $)

277 Months Ended

0 Months Ended

0 Months Ended

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2013

Dec. 31, 2012

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Jun. 30, 2013

Mar. 31, 2014

Feb. 28, 2014

Feb. 28, 2014

Senior convertible notes due December 31, 2019

Senior convertible notes due December 31, 2019

Senior convertible notes due December 31, 2019

Senior convertible notes due December 31, 2019

Senior convertible notes due December 31, 2019

Senior convertible notes due December 31, 2019

Senior convertible notes due December 31, 2019

Senior convertible notes due December 31, 2019

Deerfield

Deerfield

Deerfield

Deerfield

Deerfield

Deerfield

Facility Agreement

Notes Issued in Four Equal Tranches

Notes Issued in Four Equal Tranches

Tranche B notes

Tranche B notes

Maximum

Tranche

Scenario 1

Scenario 2

Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Deficit accumulated during the development stage

$2,348,458,000

$2,296,402,000

'

'

'

'

'

'

'

'

'

'

Goodwill impairment

151,428,000

'

'

'

'

'

'

'

'

'

'

'

Cash flow from operation since inception

-1,761,983,000

'

'

'

'

'

'

'

'

'

'

'

Cash and cash equivalents

35,759,000

70,790,000

28,005,000

61,840,000

'

'

'

'

'

'

'

'

Available borrowings under loan agreement

30,100,000

'

'

'

'

'

'

'

'

'

'

'

Accrued interest on loan arrangement

1,300,000

'

'

'

'

'

'

'

'

'

'

'

Debt facility principal amount

'

'

'

'

120,000,000

'

'

'

160,000,000

120,000,000

90,000,000

20,000,000

Number of equal tranches

'

'

'

'

'

'

'

'

4

'

'

'

Debt facility periodic principal amount

'

'

'

'

'

'

'

'

40,000,000

'

'

'

Debt facility carrying amount

'

'

'

'

25,900,000

102,300,000

40,000,000

'

'

40,000,000

'

'

Percentage of principal amount converted in to common stock

'

'

'

'

'

'

'

'

'

'

150.00%

33.33%

Maximum available amount of credit facility under covenant restrictions

'

'

'

'

'

'

'

$25,000,000

'

'

'

'

Recovered_Sheet2

Accrued Expenses and Other Current Liabilities (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Expenses and Other Current Liabilities [Line Items]	'	'
Salary and related expenses	$6,650	$12,193
Research and clinical trial costs	1,304	1,311
Accrued interest	958	2,082
Construction in progress	370	342
Other	5,724	5,706
Accrued expenses and other current liabilities	$15,006	$21,634

StockBased_Compensation_Expens

Stock-Based Compensation Expense Recognized in Condensed Consolidated Statements of Operations (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock-based compensation	$10,937	$5,189

Accounting_for_Stock_Based_Com

Accounting for Stock- Based Compensation - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Share based payment award , vesting period	'4 years
Fair value of restricted stock units	46,400
Number of restricted stock options	17,700
Weighted average vesting period for unrecognized compensation cost	'1 year 10 months 6 days
Restricted Stock Units (RSUs)	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Fair value of Restricted stock options granted , value	296,000
Weighted average grant date fair value of the stock options granted	6.39
Unrecognized compensation cost related to non vested stock options	9,900,000
Stock Options	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Fair value of the stock options granted , value	81,000
Weighted average grant date fair value of the stock options granted	4.58
Unrecognized compensation cost related to non vested stock options	14,000,000
Performance Based Restricted Stock Units	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Unrecognized compensation cost related to non vested stock options	107,000
Performance Based Stock Options	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Unrecognized compensation cost related to non vested stock options	3,700,000

Net_Loss_per_Common_Share_Addi

Net Loss per Common Share - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Net Income Loss Per Common Share [Line Items]	'	'
Companies common stock share outstanding	9,000,000	'
Antidilutive securities	67,791,150	133,500,568
Shares loaned under the share lending arrangement	9,000,000	9,000,000

Recovered_Sheet3

State Research and Development Credit Exchange Receivable - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Accounts and Other Receivables [Line Items]	'	'
Percentage of credit exchange receivable	65.00%	'
Estimated amounts receivable under program	$380,000	$298,000

Property_and_Equipment_Detail

Property and Equipment (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Property and equipment - gross	$289,919	$287,617
Less accumulated depreciation and amortization	-113,582	-111,060
Property and equipment - net	176,337	176,557
Land	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment - gross	5,273	5,273
Buildings	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment - gross	54,948	54,948
Buildings | Minimum	'	'
Property, Plant and Equipment [Line Items]	'	'
Estimated Useful Life (Years)	'39 years	'
Buildings | Maximum	'	'
Property, Plant and Equipment [Line Items]	'	'
Estimated Useful Life (Years)	'40 years	'
Building Improvements	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment - gross	114,099	114,099
Building Improvements | Minimum	'	'
Property, Plant and Equipment [Line Items]	'	'
Estimated Useful Life (Years)	'5 years	'
Building Improvements | Maximum	'	'
Property, Plant and Equipment [Line Items]	'	'
Estimated Useful Life (Years)	'40 years	'
Machinery and Equipment	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment - gross	82,189	82,189
Machinery and Equipment | Minimum	'	'
Property, Plant and Equipment [Line Items]	'	'
Estimated Useful Life (Years)	'3 years	'
Machinery and Equipment | Maximum	'	'
Property, Plant and Equipment [Line Items]	'	'
Estimated Useful Life (Years)	'15 years	'
Furniture, fixtures and office equipment	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment - gross	5,046	5,046
Furniture, fixtures and office equipment | Minimum	'	'
Property, Plant and Equipment [Line Items]	'	'
Estimated Useful Life (Years)	'5 years	'
Furniture, fixtures and office equipment | Maximum	'	'
Property, Plant and Equipment [Line Items]	'	'
Estimated Useful Life (Years)	'10 years	'
Computer Equipment and Software	'	'
Property, Plant and Equipment [Line Items]	'	'
Estimated Useful Life (Years)	'3 years	'
Property and equipment - gross	11,306	11,289
Leasehold Improvements	'	'
Property, Plant and Equipment [Line Items]	'	'
Estimated Useful Life (Years)	'4 years	'
Property and equipment - gross	17	17
Construction in Progress	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment - gross	$17,041	$14,756

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2014
Depreciation and Other Amortization Expenses [Line Items]	'
Amortization period of lease hold improvements	'4 years

Depreciation_and_Amortization_

Depreciation and Amortization Expense (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Depreciation and amortization expense	$2,522	$2,990

Common_and_Preferred_Stock_Add

Common and Preferred Stock - Additional Information (Detail) (USD $)	3 Months Ended							0 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Dec. 31, 2013	Aug. 18, 2010	Mar. 31, 2014	Feb. 28, 2014	Jun. 30, 2013	Mar. 31, 2014
			Senior convertible notes due August 15, 2015	Senior convertible notes due August 15, 2015	Senior convertible notes due August 15, 2015	Senior convertible notes due December 31, 2019	Deerfield	Deerfield	Deerfield
							Senior convertible notes due December 31, 2019	Senior convertible notes due December 31, 2019	Senior convertible notes due December 31, 2019
								Notes Issued in Four Equal Tranches	Notes Issued in Four Equal Tranches
								Tranche
Class of Stock [Line Items]	'	'	'	'	'	'	'	'	'
Common stock, shares authorized	550,000,000	550,000,000	'	'	'	'	'	'	'
Common stock, par value	$0.01	$0.01	'	'	'	'	'	'	'
Undesignated preferred stock, shares authorized	10,000,000	'	'	'	'	'	'	'	'
Undesignated preferred stock, par value	$0.01	$0.01	'	'	'	'	'	'	'
Common stock, shares issued	386,934,914	369,391,972	'	'	'	'	'	'	'
Common stock, shares outstanding	386,934,914	369,391,972	'	'	'	'	'	'	'
Common stock loaned under share lending agreement, shares	9,000,000	9,000,000	'	'	'	'	'	'	'
Principal amount	'	'	$100,000,000	$100,000,000	$100,000,000	$120,000,000	'	$160,000,000	$120,000,000
Nominal lending fee	$0.01	'	'	'	'	'	'	'	'
Maximum sales amount under the agreement	'	'	'	'	'	'	'	160,000,000	'
Number of equal tranches	'	'	'	'	'	'	'	4	'
Debt facility periodic principal amount	'	'	'	'	'	'	'	40,000,000	'
Aggregate principal amount of convertible notes	'	'	'	'	'	'	$60,000,000	'	'
Common shares issuable upon conversion	'	'	'	'	'	'	12,000,000	'	'
Conversion price of shares	'	'	'	'	$6.80	'	$5	'	'

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (Deerfield, Milestone Rights Liability, Maximum, USD $)	Jul. 01, 2013
In Millions, unless otherwise specified
Deerfield | Milestone Rights Liability | Maximum	'
Commitments and Contingencies [Line Items]	'
Contingent liability for milestone payments	$90

RelatedParty_Arrangements_Addi

Related-Party Arrangements - Additional Information (Detail) (USD $)	Mar. 31, 2014	Oct. 31, 2013	Oct. 31, 2007	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Oct. 31, 2013	Mar. 31, 2014	Mar. 31, 2014
In Millions, unless otherwise specified		Principal stockholder	Principal stockholder	Principal stockholder	Principal stockholder	Principal stockholder	Principal stockholder	Related Party Debt	Related Party Debt
				Loan Arrangement	Loan Arrangement	Loan Arrangement	Amended Agreement	Letter Agreement	Letter Agreement
					Maximum	Minimum			LIBOR
Related Party Transaction [Line Items]	'	'	'	'	'	'	'	'	'
Loan agreement with related party	'	$370	$350	'	'	'	'	'	'
Promissory note maturity date	'	'	'	'	'	'	5-Jan-20	'	'
Principal amount outstanding under credit facility	'	'	'	49.5	'	'	'	'	'
Amount available for future borrowings	30.1	'	'	30.1	'	'	'	'	'
Fixed borrowing rate	'	'	'	5.84%	'	'	'	'	'
Interest payable	1.3	'	'	1.3	'	'	'	'	'
Amount prepaid for cancellation of indebtedness	'	'	'	'	200	'	'	'	'
Number of months advances outstanding	'	'	'	'	'	'12 months	'	'	'
Related party transaction prepayment period	'	'	'	'90 days	'	'	'	'	'
Aggregate principal amount cancelled	'	'	'	$105	'	'	'	'	'
Interest rate (LIBOR)	'	'	'	'	'	'	'	'	5.00%
Description of variable rate interest	'	'	'	'	'	'	'	'The interest rate will increase to the one-year LIBOR calculated on the date of the initial advance or in effect on the date of default, whichever is greater, plus 5% per annum.	'

Summary_of_Senior_Convertible_

Summary of Senior Convertible Notes (Detail) (Senior convertible notes due August 15, 2015, USD $)	Mar. 31, 2014	Dec. 31, 2013	Aug. 18, 2010
In Thousands, unless otherwise specified
Senior convertible notes due August 15, 2015	'	'	'
Debt Instrument [Line Items]	'	'	'
Principal amount	$100,000	$100,000	$100,000
Unaccreted debt issuance expense	-1,338	-1,561	'
Net carrying amount	$98,662	$98,439	'

Senior_Convertible_Notes_Addit

Senior Convertible Notes - Additional Information (Detail) (USD $)	3 Months Ended		0 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Aug. 18, 2010	Mar. 31, 2014	Dec. 31, 2013
			Senior convertible notes due August 15, 2015	Senior convertible notes due August 15, 2015	Senior convertible notes due August 15, 2015
			D
Debt Instrument [Line Items]	'	'	'	'	'
Principal amount	'	'	$100,000,000	$100,000,000	$100,000,000
Senior notes, effective interest rate	'	'	5.75%	5.75%	'
Accrued interest	1,300,000	'	'	1,000,000	2,400,000
No of convertible shares	'	'	147.0859	'	'
Principal amount per share	'	'	$1,000	'	'
Conversion price of shares	'	'	$6.80	'	'
Percentage of repurchase price	'	'	100.00%	'	'
Percentage of conversion price equaling stock price	'	'	150.00%	'	'
Trading days	'	'	20	'	'
Consecutive trading days	'	'	'30 days	'	'
Issuance cost	'	'	4,200,000	'	'
Accretion of debt issuance costs	$223,000	$209,000	'	'	'

Components_and_Activity_of_Fac

Components and Activity of Facility Agreement (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Jul. 01, 2013
In Thousands, unless otherwise specified
Securities Financing Transaction [Line Items]	'	'	'
Net carrying amount of facility financing agreement	$25,871	$102,300	'
Initial commitment asset fair value	13,393	'	'
Commitment asset value included in other assets	8,078	'	'
Tranche B notes	'	'	'
Securities Financing Transaction [Line Items]	'	'	'
Tranche B commitment asset fair value	2,921	'	'
Tranche Two	'	'	'
Securities Financing Transaction [Line Items]	'	'	'
Less portion of commitment asset	-3,656	'	'
Tranche Three	'	'	'
Securities Financing Transaction [Line Items]	'	'	'
Less portion of commitment asset	-4,580	'	'
Senior convertible notes due December 31, 2019	'	'	'
Securities Financing Transaction [Line Items]	'	'	'
Initial principal amount	120,000	'	'
Principal converted to equity	-92,500	'	'
Debt discount-net of amortization	-1,546	'	'
Unaccreted debt issuance expense	-83	'	'
Net carrying amount of facility financing agreement	25,871	'	'
Net carrying amount included in other liabilities	25,900	102,300	'
Tranche B commitment asset fair value	'	'	2,900
Milestone Rights Liability	'	'	'
Securities Financing Transaction [Line Items]	'	'	'
Initial principal amount	16,276	'	'
Debt discount-net of amortization	-51	'	'
Unaccreted debt issuance expense	-61	'	'
Less current portion of milestone rights included in other current liabilities	-3,151	'	'
Net carrying amount included in other liabilities	$13,013	'	'

Accretion_of_Debt_Issuance_Cos

Accretion of Debt Issuance Cost and Debt Discount in Connection with Deerfield Financing (Detail) (Deerfield, USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Deerfield	'
Debt Instrument [Line Items]	'
Accretion expense- debt issuance cost	$282
Accretion expense- debt discount	$6,367

Facility_Financing_Agreement_A

Facility Financing Agreement - Additional Information (Detail) (USD $)

277 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

Mar. 31, 2014

Feb. 28, 2014

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

Jul. 01, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Feb. 28, 2014

Feb. 28, 2014

Feb. 28, 2014

Feb. 28, 2014

Feb. 28, 2014

Jun. 30, 2013

Mar. 31, 2014

Feb. 28, 2014

Feb. 28, 2014

Jan. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Tranche B notes

Tranche B notes

Senior convertible notes due December 31, 2019

Senior convertible notes due December 31, 2019

Senior convertible notes due December 31, 2019

Senior convertible notes due December 31, 2019

Senior convertible notes due December 31, 2019

Deerfield

Deerfield

Deerfield

Deerfield

Deerfield

Deerfield

Deerfield

Deerfield

Deerfield

Deerfield

Deerfield

Deerfield

Deerfield

Deerfield

Deerfield

Fourth Tranche

Tranche B notes

Senior convertible notes due December 31, 2019

Senior convertible notes due December 31, 2019

Senior convertible notes due December 31, 2019

Senior convertible notes due December 31, 2019

Senior convertible notes due December 31, 2019

Senior convertible notes due December 31, 2019

Senior convertible notes due December 31, 2019

Senior convertible notes due December 31, 2019

Senior convertible notes due December 31, 2019

Senior convertible notes due December 31, 2019

Senior convertible notes due December 31, 2019

Senior convertible notes due December 31, 2019

Senior convertible notes due December 31, 2019

Senior convertible notes due December 31, 2019

Senior convertible notes due December 31, 2019

Maximum

Tranche B notes

Tranche B notes

Tranche B notes

Tranche B notes

Notes Issued in Four Equal Tranches

Notes Issued in Four Equal Tranches

Tranche B notes

Tranche B notes

Tranche Two

Tranche Two

Tranche One and Tranche Three

Tranche Three

Tranche One

Scenario 1

Scenario 2

If the Company enters into a collaboration with a third party to commercialize AFFREZZA

Tranche

Scenario 1

Scenario 2

Minimum

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of common shares issued upon conversion

'

'

'

$120,000,000

'

'

'

'

'

'

'

$90,000,000

$20,000,000

'

$160,000,000

$120,000,000

$90,000,000

$20,000,000

'

'

'

'

'

Number of equal tranches

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4

'

'

'

'

'

'

'

'

Debt facility periodic principal amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

40,000,000

'

'

'

'

'

'

'

'

Debt facility carrying amount

'

'

'

25,900,000

102,300,000

'

'

'

40,000,000

'

'

'

'

'

'

40,000,000

'

'

'

'

'

'

'

Senior notes, effective interest rate

'

'

'

'

'

'

'

'

'

'

9.75%

'

'

8.75%

9.75%

'

'

'

'

'

'

'

'

Percentage of principal amount converted in to common stock

'

'

'

'

'

'

'

'

'

'

'

150.00%

33.33%

'

'

'

150.00%

33.33%

'

'

'

'

'

Repayment as a percentage of original principal amount

'

'

'

'

'

'

'

'

'

'

25.00%

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument maturity date

'

31-Dec-19

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate principal amount of convertible notes

'

'

'

'

'

'

'

'

'

60,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Common shares issuable upon conversion

'

'

'

'

'

'

'

'

'

12,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion price of shares

'

'

'

'

'

'

'

'

'

$5

'

'

'

'

'

'

'

'

'

'

'

'

'

Commitment asset at fair value

'

'

2,921,000

'

'

2,900,000

40,000,000

90,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of common shares issued upon conversion

3,331,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

33,500,000

6,500,000

60,000,000

40,000,000

12,500,000

Common shares issued upon conversion

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,559,251

1,293,224

'

7,121,120

2,142,709

Loss on debt conversion

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

600,000

'

'

'

Debt extinguishment costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3,000,000

'

$3,000,000

'

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments - Additional Information (Detail) (USD $)

3 Months Ended

0 Months Ended

3 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Jul. 01, 2013

Feb. 28, 2014

Jul. 01, 2013

Jul. 01, 2013

Mar. 31, 2014

Aug. 18, 2010

Mar. 31, 2014

Mar. 31, 2014

Senior convertible notes due December 31, 2019

Senior convertible notes due December 31, 2019

Senior convertible notes due December 31, 2019

Senior convertible notes due December 31, 2019

Senior convertible notes due August 15, 2015

Senior convertible notes due August 15, 2015

Commitment Asset

Milestone Rights Liability

Fair Value, Inputs, Level 3

Fair Value, Inputs, Level 3

Fair Value, Inputs, Level 3

Fair Value, Inputs, Level 3

Fair Value, Inputs, Level 3

Income Approach Valuation Technique

Income Approach Valuation Technique

Income Approach Valuation Technique

Income Approach Valuation Technique

Tranche One

Fair Value of Financial Instruments [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Cash equivalents

$35,759,000

$28,005,000

$70,790,000

$61,840,000

'

'

'

'

'

'

'

'

Cash equivalents, money market funds

34,900,000

'

67,700,000

'

'

'

'

'

'

'

'

'

Senior notes, effective interest rate

'

'

'

'

'

'

'

'

5.75%

5.75%

'

'

Market discount rate

'

'

'

'

'

'

12.70%

12.50%

'

'

12.00%

17.50%

Additional commitment asset

'

'

'

'

2,900,000

2,900,000

'

'

'

'

'

'

Percentage of market yield

'

'

'

'

'

11.90%

'

'

'

'

'

'

Transfers of assets between fair value measurement

0

0

'

'

'

'

'

'

'

'

'

'

Transfers of liabilities between fair value measurement

$0

$0

'

'

'

'

'

'

'

'

'

'

Summary_of_Carrying_Values_and

Summary of Carrying Values and Estimated Fair Values of Senior Convertible Notes (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Senior convertible notes due August 15, 2015	'	'
Convertible Debt [Line Items]	'	'
Carrying value	$98,662,000	$98,439,000
Estimated fair value	95,100,000	102,200,000
Senior convertible notes due December 31, 2019	'	'
Convertible Debt [Line Items]	'	'
Carrying value	25,900,000	102,300,000
Estimated fair value	$25,700,000	$107,000,000

Subsequent_Event_Additional_In

Subsequent Event - Additional Information (Detail) (USD $)	277 Months Ended	3 Months Ended		0 Months Ended
	Mar. 31, 2014	Mar. 31, 2014	6-May-14	Apr. 02, 2014	Apr. 02, 2014
		Tranche One	Subsequent Event	Subsequent Event	Subsequent Event
		Senior convertible notes due December 31, 2019	Tranche B notes	Tranche One	Tranche One and Tranche Three
		Deerfield		Senior convertible notes due December 31, 2019	Senior convertible notes due December 31, 2019
				Deerfield	Deerfield
Subsequent Event [Line Items]	'	'	'	'	'
Amount of common shares issued upon conversion	$3,331,000	$12,500,000	'	$7,500,000	$60,000,000
Common shares issued upon conversion	'	2,142,709	'	1,500,000	10,763,829
Principal amount of notes purchased	'	'	$20,000,000	'	'